Researchers at Glucotrack, Inc. have developed a new continuous blood glucose monitoring (CBGM) system that could change the way people with diabetes manage their condition. This fully implantable technology promises to provide more accurate blood sugar readings without the need for on-body wearables. With a sensor designed to last up to three years, it addresses key challenges faced by those who rely on traditional glucose monitoring methods.

This advancement is particularly relevant for individuals living with diabetes who want to maintain stable blood sugar levels, which is crucial for preventing complications and promoting overall health. The new device aims to simplify glucose monitoring, potentially leading to better management of blood sugar levels and improved quality of life for users. The technology is currently in the investigational phase, with studies showing promising results in terms of accuracy and stability.

The evidence supporting Glucotrack’s CBGM comes from peer-reviewed studies that demonstrate the sensor’s long-term performance. One study showed sustained accuracy over 240 days in an animal model, while another confirmed the stability of the glucose oxidase enzyme for a year. Although this research is a step forward, it is important to note that the device has not yet been approved for use in humans. Glucotrack has submitted an application to the FDA to begin clinical studies, which will be essential for determining its effectiveness in real-world settings.

For those interested in the future of diabetes management, staying informed about developments in continuous monitoring technology could be beneficial. While this device is still in the testing phase, it represents a significant leap towards making glucose monitoring easier and more reliable for millions of people living with diabetes.

Source: globenewswire.com